Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-100 in advanced solid tumors
NCT03781362Phase 1Completed
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CPI-100 in solid tumor (advanced stage) (2 arms), sponsored by Coordination Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose at 42 days. Started Dec 2018; status: completed.
02
Drugs
CPI-100
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03781362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781362.